Back to VRX Stock Lookup

VRX Related Analyst Ratings

May 20, 2013 11:43 AM UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through

Apr 29, 2013 10:34 AM Actavis (ACT) / Valeant (VRX) Deal Rumored Down But Not Out

Apr 4, 2013 01:33 PM Valeant (VRX) May Tuck Tail if Obagi (OMPI) Bidding War Heats Up - Analyst

Apr 2, 2013 10:57 AM Obagi Medical (OMPI) Bidding War Could Take Stock as High as $27/Share

Mar 27, 2013 12:53 PM Ameriprise Financial Starts Valeant Pharmaceuticals (VRX) at Buy

Mar 21, 2013 01:00 PM Obagi an Excellent Fit for Valeant Pharmaceuticals (VRX), Says Analyst

Jan 29, 2013 01:12 PM Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results

Sep 14, 2012 02:17 PM Morgan Stanley Downgrades Valeant Pharmaceuticals (VRX) to Equalweight

Sep 7, 2012 07:21 AM Jefferies Maintains a 'Buy/Top Pick' on Valeant Pharmaceuticals (VRX); Taking the Right Medic(is)ine

Sep 5, 2012 01:39 PM Barclays Maintains an 'Equalweight' on Medicis (MRX); Is Another Bidder Out There?

Sep 5, 2012 10:16 AM UBS Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Deal Supports Thesis; Stock Move Justified

Sep 5, 2012 08:37 AM Goldman Sachs Downgrades Medicis (MRX) to Neutral; Limited Upside From Deal Now

Sep 4, 2012 03:22 PM Barclays on Medicis (MRX)/Valeant (VRX) Deal: Surprise...or Not Really?

Sep 4, 2012 09:21 AM Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Key Question Around Acquisition Is...

Sep 4, 2012 09:02 AM Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Acquisition Rewarding Patient Investors

Jul 13, 2012 08:55 AM Goldman Sachs Resumes Coverage on Valeant Pharmaceuticals (VRX) at Neutral; Upside Tied to Relief of Organic Growth Concerns

Jul 9, 2012 10:51 AM Analyst Says Obagi (OMPI) Could Soon See Offers from 'Multiple Suitors'

Jul 3, 2012 01:18 PM UBS Q2 Preview on U.S. Pharmaceuticals: Safe Havens in Generic, Specialty and Large-Cap

Jun 22, 2012 10:54 AM Jefferies Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Analyst Day: Controversial...Yet An Excellent Investment

May 3, 2012 02:08 PM CRT Capital Cuts Valeant Pharma (VRX) to Fairly Valued

Apr 10, 2012 01:26 PM UBS on U.S. Pharma - Large Cap and Specialty: Q1 Preview - Off to a Good Start

Jan 26, 2012 08:44 AM Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Neutral

Jan 12, 2012 01:55 PM UBS on U.S. Pharma – Large Cap and Specialty: 4Q11 Preview: Things Still Look Interesting

Jan 10, 2012 06:52 AM Morgan Stanley Upgrades Valeant Pharmaceuticals (VRX) to Overweight

Jan 9, 2012 11:42 AM Jefferies Boosts PT on Valeant (VRX) to $75; FY12 Outlook Surprises to Upside

Dec 22, 2011 12:48 PM Wells Fargo Raises Valuation Range on Valeant Pharm (VRX), Synergy Opportunities Could be Limited

Sep 12, 2011 06:54 AM Morgan Stanley Starts Valeant Pharmaceuticals (VRX) at Equalweight

May 10, 2011 11:02 AM Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q1 Results: Delivering on Synergies

May 10, 2011 10:27 AM Goldman Sachs Resumes Coverage on Valeant Pharmaceuticals (VRX) at Neutral

May 6, 2011 11:51 AM Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q1 Preview: Focusing on The Task at Hand

May 4, 2011 12:46 PM UBS Maintains a 'Neutral' on Cephalon (CEPH); Distracted 1Q11

May 3, 2011 11:21 AM Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Withdraws Bid After Teva Makes Better Offer for Cephalon

May 2, 2011 03:02 PM Collins Stewart Reiterates a 'Buy' on Valeant Pharmaceuticals (VRX); Weakness Related To CEPH Is A Good Buying Opportunity

Apr 11, 2011 11:04 AM UBS maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Increasing PT for CEPH Deal

Mar 31, 2011 11:09 AM Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Underestimating Synergies with Cephalon

Mar 31, 2011 10:06 AM UPDATE - UBS Downgraded Cephalon (CEPH) to Neutral; Likely Some Upside To Offer price, but Not Material

Mar 31, 2011 07:31 AM UBS Downgrades Cephalon (CEPH) to Neutral

Mar 31, 2011 07:19 AM TD Newcrest Upgrades Valeant Pharmaceuticals (VRX) to Buy; Agressive Acquisition Agenda

Mar 30, 2011 03:36 PM Wall Street Mixed On Additional Upside in Cephalon (CEPH) Following Takeover Bid

Mar 30, 2011 01:58 PM Stifel Nicolaus Cuts Cephalon (CEPH) to Hold

Mar 30, 2011 12:48 PM Barclays Maintains an 'Underweight' on Cephalon (CEPH); Valeant Offer Provides Exit from Core Risk

Mar 30, 2011 09:16 AM Caris Upgrades Cephalon (CEPH) to Average

Mar 30, 2011 08:46 AM Soleil Securities Maintains a 'Buy' on Cephalon (CEPH); Bid Likely to be Near-Term High

Mar 30, 2011 07:44 AM Morgan Stanley Upgrades Cephalon (CEPH), JMP Downgrades to Market Perform

Feb 25, 2011 12:21 PM UBS Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Everything’s Still Peachy Here

Feb 25, 2011 11:47 AM Jefferies Raises Price Target on Valeant Pharmaceuticals (VRX), Maintains Buy Rating

Feb 25, 2011 11:35 AM Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q4 Results: Squeezing Out Every Last Drop

Feb 22, 2011 11:37 AM Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q4 Preview: Looking For A Legacy Rebound

Feb 14, 2011 07:19 AM Collins Stewart Starts Valeant Pharmaceuticals (VRX) at Buy

Feb 8, 2011 12:48 PM TD Newcrest Raises Price Target on Valeant Pharmaceuticals (VRX), Maintains Hold Rating

Back to VRX Stock Lookup